UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pulmonary Arterial Hypertension

Journal of the American College of Cardiology, 2008-04, Vol.51 (16), p.1527-1538

2008

Volltextzugriff (PDF)

Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality

Journal of the American College of Cardiology, 2018-02, Vol.71 (7), p.752-763

2018

Volltextzugriff (PDF)

Left atrial structure and function and clinical outcomes in the general population

European heart journal, 2013-01, Vol.34 (4), p.278-285

2013

Volltextzugriff (PDF)

Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study

The Journal of heart and lung transplantation, 2019-01, Vol.38 (1), p.43-50

2019

Volltextzugriff (PDF)

The right ventricle in pulmonary hypertension

Coronary artery disease, 2005-02, Vol.16 (1), p.13-18

2005

Volltextzugriff (PDF)

Pregnancy and Congenital Heart Disease–Associated Pulmonary Hypertension: Are Outcomes Improving?

Circulation (New York, N.Y.), 2023-02, Vol.147 (7), p.562-564

2023

Volltextzugriff (PDF)

Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study

Respiratory research, 2021-02, Vol.22 (1), p.34-9, Article 34

2021

Volltextzugriff (PDF)

Macitentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH): Real-World Evidence from the Combined OPUS/OrPHeUS Dataset

Cardiology and therapy, 2024-06, Vol.13 (2), p.315-339

2024

Volltextzugriff (PDF)

Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies

Pulmonary therapy, 2024-03, Vol.10 (1), p.85-107

2024

Volltextzugriff (PDF)

Hemodynamic effects of fluoxetine in pulmonary arterial hypertension: an open label pilot study

Pulmonary circulation, 2020-10, Vol.10 (4), p.1-4

2020

Volltextzugriff (PDF)

Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study

The American heart journal, 2014-02, Vol.167 (2), p.218-225.e1

2014

Volltextzugriff (PDF)

Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension

ERJ open research, 2023-01, Vol.9 (1), p.456-2022

2023

Volltextzugriff (PDF)

Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension

Journal of the American College of Cardiology, 2021-10, Vol.78 (14), p.1393-1403

2021

Volltextzugriff (PDF)

Right Heart Adaptation to Pulmonary Arterial Hypertension: Physiology and Pathobiology

Journal of the American College of Cardiology, 2013-12, Vol.62 (25), p.D22-D33

2013

Volltextzugriff (PDF)

Prognosis of pulmonary arterial hypertension patients with pericardial effusion before and after initiation of parenteral prostacyclin therapy

Pulmonary circulation, 2023-04, Vol.13 (2), p.e12226-n/a

2023

Volltextzugriff (PDF)

Safety of macitentan for the treatment of pulmonary hypertension: Real‐world experience from the OPsumit® USers Registry (OPUS) and OPsumit® Historical USers cohort (OrPHeUS)

Pulmonary circulation, 2022-10, Vol.12 (4), p.e12150-n/a

2022

Volltextzugriff (PDF)

Reply: Reduction in Risk of Disease Progression With Triple Therapy: Is it True for All?

Journal of the American College of Cardiology, 2022-02, Vol.79 (7), p.e177-e177

2022

Volltextzugriff (PDF)

Pulmonary Arterial Hypertension—Symptoms and Impact Questionnaire: feasibility of utilizing one-day versus seven-day symptom reporting

Pulmonary circulation, 2020-04, Vol.10 (2), p.1-9

2020

Volltextzugriff (PDF)

Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension

Journal of the American College of Cardiology, 2024-01, Vol.83 (4), p.473-484

2024

Volltextzugriff (PDF)

Lessons from the COMPASS-3 Study

Pulmonary circulation, 2018-01, Vol.8 (1), p.1-3

2018

Volltextzugriff (PDF)

Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension: Insights From the Phase III GRIPHON Study

Circulation (New York, N.Y.), 2019-05, Vol.139 (21), p.2440-2450

2019

Volltextzugriff (PDF)

Efficacy and Safety of Exercise Training in Chronic Pulmonary Hypertension: Systematic Review and Meta-Analysis

Circulation. Heart failure, 2015-11, Vol.8 (6), p.1032-1043

2015

Volltextzugriff (PDF)

MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study

The European respiratory journal, 2024-09, Vol.64 (5), p.2401110

2024

Volltextzugriff (PDF)

The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study

European journal of heart failure, 2022-01, Vol.24 (1), p.205-214

2022

Volltextzugriff (PDF)

Treatment algorithm for pulmonary arterial hypertension

The European respiratory journal, 2024-10, Vol.64 (4), p.2401325

2024

Volltextzugriff (PDF)

1 – 25 von 218

Suche als RSS-Feed

Aktive Filter

KollektionSingle Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(196)
Mit Volltextzugriff
(191)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(145)
Life Sciences & Biomedicine
(126)
Humans
(82)
Female
(48)
Male
(47)
Cardiovascular System & Cardiology
(38)
Cardiac & Cardiovascular Systems
(37)
Adult
(28)
Middle Aged
(28)
Respiratory System
(22)
Aged
(21)
Pulmonary Arterial Hypertension
(21)
Animals
(19)
Pulmonary Hypertension
(18)
Biological And Medical Sciences
(15)
Internal Medicine
(15)
Medical Sciences
(14)
Treatment Outcome
(14)
Adolescent
(13)
Hypertension, Pulmonary - Drug Therapy
(12)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality

Left atrial structure and function and clinical outcomes in the general population

Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study

The right ventricle in pulmonary hypertension

Pregnancy and Congenital Heart Disease–Associated Pulmonary Hypertension: Are Outcomes Improving?

Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study

Macitentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH): Real-World Evidence from the Combined OPUS/OrPHeUS Dataset

Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies

Hemodynamic effects of fluoxetine in pulmonary arterial hypertension: an open label pilot study

Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study

Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension

Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension

Right Heart Adaptation to Pulmonary Arterial Hypertension: Physiology and Pathobiology

Prognosis of pulmonary arterial hypertension patients with pericardial effusion before and after initiation of parenteral prostacyclin therapy

Safety of macitentan for the treatment of pulmonary hypertension: Real‐world experience from the OPsumit® USers Registry (OPUS) and OPsumit® Historical USers cohort (OrPHeUS)

Reply: Reduction in Risk of Disease Progression With Triple Therapy: Is it True for All?

Pulmonary Arterial Hypertension—Symptoms and Impact Questionnaire: feasibility of utilizing one-day versus seven-day symptom reporting

Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension

Lessons from the COMPASS-3 Study

Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension: Insights From the Phase III GRIPHON Study

Efficacy and Safety of Exercise Training in Chronic Pulmonary Hypertension: Systematic Review and Meta-Analysis

MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study

The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study

Treatment algorithm for pulmonary arterial hypertension

Aktive Filter

Suchergebnisse filtern